Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on September 27, 2018. The report covers a specific corporate event occurring on the same date regarding the company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the completion of the second dosing cohort for Onvansertib, the company's first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor. This milestone was achieved in a Phase 1b/2 clinical trial for patients with Acute Myeloid Leukemia (AML), where the drug was administered in combination with standard-of-care decitabine.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies. The primary commentary is the announcement of the clinical trial milestone. No unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for detailed safety and efficacy data from the second dosing cohort.
- Confirm the status of the Phase 1b/2 trial for Onvansertib in Acute Myeloid Leukemia.
- Check subsequent filings for any financial impact or updated guidance resulting from this clinical milestone.